Literature DB >> 16279588

Early onset of ganciclovir-resistant cytomegalovirus infection in a lung-transplant recipient.

Fengshi Chen1, Toru Bando, Nobuharu Hanaoka, Tatsuo Fukuse, Seiki Hasegawa, Hiromi Wada.   

Abstract

Ganciclovir resistance in cytomegalovirus (CMV) is an increasing problem in lung-transplant recipients with adverse clinical outcomes. We experienced the successful treatment of ganciclovir-resistant CMV infection in a lung-transplant recipient still receiving CMV prophylaxis. A 24-year-old woman with lymphangioleiomyomatosis underwent a living-donor lobar lung transplantation. She was a primary CMV mismatch (D+/R-) patient. She recovered from her postoperative complications, and was about to be discharged. However, she suffered ganciclovir-resistant CMV infection during prophylactic therapy. She was successfully treated with foscarnet, and is now alive without recurrence 18 months after surgery.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16279588     DOI: 10.1007/s11748-005-0068-9

Source DB:  PubMed          Journal:  Jpn J Thorac Cardiovasc Surg        ISSN: 1344-4964


  10 in total

1.  A 42-year-old lung transplant patient with ganciclovir-resistant cytomegalovirus (CMV) infection.

Authors:  N Basgoz
Journal:  Transpl Infect Dis       Date:  1999-09       Impact factor: 2.228

2.  High incidence of ganciclovir-resistant cytomegalovirus infection among lung transplant recipients receiving preemptive therapy.

Authors:  Ajit P Limaye; Ganesh Raghu; David M Koelle; James Ferrenberg; Meei-Li Huang; Michael Boeckh
Journal:  J Infect Dis       Date:  2001-12-14       Impact factor: 5.226

3.  Failure of ganciclovir treatment associated with selection of a ganciclovir-resistant cytomegalovirus strain in a lung transplant recipient.

Authors:  S Alain; P Honderlick; D Grenet; M Stern; C Vadam; M J Sanson-Le Pors; M C Mazeron
Journal:  Transplantation       Date:  1997-05-27       Impact factor: 4.939

4.  The impact of ganciclovir-resistant cytomegalovirus infection after lung transplantation.

Authors:  R M Kruger; W D Shannon; M Q Arens; J P Lynch; G A Storch; E P Trulock
Journal:  Transplantation       Date:  1999-11-15       Impact factor: 4.939

5.  Molecular analysis of human cytomegalovirus strains from two lung transplant recipients with the same donor.

Authors:  N S Lurain; H C Ammons; K S Kapell; V V Yeldandi; E R Garrity; J P O'Keefe
Journal:  Transplantation       Date:  1996-08-27       Impact factor: 4.939

Review 6.  Resistance of human cytomegalovirus to antiviral drugs.

Authors:  A Erice
Journal:  Clin Microbiol Rev       Date:  1999-04       Impact factor: 26.132

7.  Clinical characteristics of 13 solid organ transplant recipients with ganciclovir-resistant cytomegalovirus infection.

Authors:  C M Isada; B Yen-Lieberman; N S Lurain; R Schilz; D Kohn; D L Longworth; A J Taege; S B Mossad; J Maurer; S M Flechner; S D Mawhorter; W Braun; S M Gordon; S K Schmitt; M Goldman; J Long; M Haug; R K Avery
Journal:  Transpl Infect Dis       Date:  2002-12       Impact factor: 2.228

8.  Human cytomegalovirus double resistance in a donor-positive/recipient-negative lung transplant patient with an impaired CD4-mediated specific immune response.

Authors:  Fausto Baldanti; Daniele Lilleri; Giulia Campanini; Giuditta Comolli; Anna Lisa Ridolfo; Stefano Rusconi; Giuseppe Gerna
Journal:  J Antimicrob Chemother       Date:  2004-01-22       Impact factor: 5.790

9.  Emergence of ganciclovir-resistant cytomegalovirus in lung transplant recipients.

Authors:  Sangeeta M Bhorade; Nell S Lurain; Ashby Jordan; Julie Leischner; Jaime Villanueva; Ramon Durazo; Steve Creech; Wickii T Vigneswaran; Edward R Garrity
Journal:  J Heart Lung Transplant       Date:  2002-12       Impact factor: 10.247

Review 10.  Antiviral resistance in cytomegalovirus: an emerging problem in organ transplant recipients.

Authors:  Ajit P Limaye
Journal:  Semin Respir Infect       Date:  2002-12
  10 in total
  1 in total

1.  Ganciclovir-resistant, cytomegalic interstitial lung disease in a patient with systemic lupus erythematosus.

Authors:  Eduardo Finger; Helio Romaldini; David Salomão Lewi; Morton Aaron Scheinberg
Journal:  Clin Rheumatol       Date:  2006-12-22       Impact factor: 2.980

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.